AZD5213
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Brain Distribution of [11C]AZ12807110 and AZD5213
Conditions
Brain Distribution of [11C]AZ12807110 and AZD5213
Trial Timeline
Nov 1, 2010 → Jun 1, 2011
NCT ID
NCT01194986About AZD5213
AZD5213 is a phase 1 stage product being developed by AstraZeneca for Brain Distribution of [11C]AZ12807110 and AZD5213. The current trial status is completed. This product is registered under clinical trial identifier NCT01194986. Target conditions include Brain Distribution of [11C]AZ12807110 and AZD5213.
What happened to similar drugs?
5 of 18 similar drugs in Brain Distribution of [11C]AZ12807110 and AZD5213 were approved
Approved (5) Terminated (2) Active (13)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01194986 | Phase 1 | Completed |
Competing Products
20 competing products in Brain Distribution of [11C]AZ12807110 and AZD5213
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Abemaciclib + Endocrine therapy | Eli Lilly | Phase 1/2 | 39 |
| Duloxetine + Sugar pill | Eli Lilly | Phase 2 | 27 |
| Neurosteroid enantiomer | Oragenics | Phase 2 | 32 |
| Patritumab deruxtecan | Daiichi Sankyo | Phase 2 | 27 |
| filgrastim + exatecan mesylate | Daiichi Sankyo | Phase 1 | 29 |
| Eribulin Mesylate | Eisai | Phase 1 | 29 |
| Pembrolizumab + Lenvatinib | Eisai | Phase 2 | 42 |
| Palonosetron (Aloxi) and Dexamethasone | Eisai | Phase 2 | 27 |
| GLIADEL | Eisai | Phase 2 | 35 |
| Nivolumab + Temozolomide | Ono Pharmaceutical | Phase 3 | 40 |
| Nivolumab + Temozolomide | Ono Pharmaceutical | Phase 3 | 40 |
| Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastim | Eli Lilly | Phase 1 | 29 |
| abemaciclib + abemaciclib | Eli Lilly | Phase 2 | 39 |
| JNJ-17299425 | Johnson & Johnson | Phase 2 | 27 |
| ABT-888 | AbbVie | Phase 1 | 29 |
| Veliparib + Placebo | AbbVie | Phase 2 | 35 |
| Iressa (Gefitinib) | AstraZeneca | Phase 2 | 27 |
| Trastuzumab deruxtecan | AstraZeneca | Phase 2 | 42 |
| Exenatide | AstraZeneca | Approved | 43 |
| Vorinostat | Merck | Phase 1 | 29 |